Lexeo Therapeutics is a clinical-stage genetic medicine company which defined cardiovascular diseases and APOE4-associated Alzheimer's disease are treated. Lexeo Therapeutics is based in New York City.
| Revenue (Most Recent Fiscal Year) | $0.65M |
| Net Income (Most Recent Fiscal Year) | $-98.33M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.08 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -85.86% |
| Return on Assets (Trailing 12 Months) | -68.48% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.42 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.42 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.65 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.99 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.09 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.30 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 33.20M |
| Free Float | 31.70M |
| Market Capitalization | $95.28M |
| Average Volume (Last 20 Days) | 0.97M |
| Beta (Past 60 Months) | 1.27 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 60.67% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |